Black Rock Inc. Assembly Biosciences, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.65 - $1.25 $74,556 - $143,378	-114,703 Reduced 10.79%	947,984 $777,000
Q3 2023 Nov 13, 2023	SELL	$0.87 - $1.13 $6,644 - $8,629	-7,637 Reduced 0.71%	1,062,687 $945,000
Q2 2023 Aug 11, 2023	SELL	$0.81 - $1.15 $13,153 - $18,674	-16,239 Reduced 1.49%	1,070,324 $1.23 Million
Q1 2023 May 12, 2023	SELL	$0.8 - $1.74 $38,834 - $84,464	-48,543 Reduced 4.28%	1,086,563 $912,000
Q4 2022 Feb 13, 2023	BUY	$1.09 - $1.52 $1,331 - $1,857	1,222 Added 0.11%	1,135,106 $1.48 Million

Q3 2022 Nov 14, 2022	SELL	$1.7 - $2.34 $38,632 - $53,176	-22,725 Reduced 1.96%	1,133,884 $1.86 Million
Q2 2022 Aug 12, 2022	SELL	$1.35 - $2.29 $9,329 - $15,826	-6,911 Reduced 0.59%	1,156,609 $2.43 Million
Q1 2022 May 12, 2022	SELL	$1.46 - $2.45 $34,454 - $57,817	-23,599 Reduced 1.99%	1,163,520 $2.4 Million
Q4 2021 Feb 10, 2022	SELL	$2.13 - $3.46 $1.67 Million - $2.71 Million	-782,858 Reduced 39.74%	1,187,119 $2.77 Million
Q3 2021 Nov 09, 2021	BUY	$3.14 - $3.9 $181,752 - $225,743	57,883 Added 3.03%	1,969,977 $6.86 Million
Q2 2021 Aug 11, 2021	BUY	$3.8 - $4.56 $7.27 Million - $8.72 Million	1,912,094 New	1,912,094 $7.42 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.